|
|
|
| Efficacy of leuprorelin combined with laparoscopic myomectomy for treating patients with uterine myoma and its influence on the pelvic ovarian function and postoperative recurrence |
| 3201 Hospital, Hanzhong, Shaanxi Province, 723000 |
|
|
|
|
Abstract To observe the efficacy of leuprorelin combined with laparoscopic myomectomy for treating patients with uterine myoma, and to study its influence on the pelvic ovarian function and postoperative recurrence of the patients. Methods: A total of 162 patients with uterine myoma were selected and were divided into control group (81 cases) and observation group (81 cases) by random number table method from March 2019 to June 2022. The patients in the control group were given treatment of laparoscopic myomectomy alone, and the patients in the observation group were given treatment of subcutaneous injection of leuprelin acetate in 3 months before surgery combined with laparoscopic myomectomy. The values of the operative related indexes and the postoperative complications rate of the patients were compared between the two groups. The changes of the uterine volume and the levels of estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) of the patients in 3 months before and after surgery were compared between the two groups. Pelvic floor Dysfunction Questionnaire (PFDI-20) was used to evaluate the pelvic floor function of the patients in the two groups. The recurrence rates of the patients in the two groups were followed up in 6 months and in 12 months after surgery. Results: The intraoperative blood loss, the operation time, the drainage time, and the activity time of getting out of bed of the patients in the observation group were significantly less than those of the patients in the control group (P<0.05). There was no significant difference in the incidence of postoperative complications (1.2% vs. 3.7%) of the patients between the two groups (P>0.05). After drug pretreatment, the volume of uterine myoma (89.62±6.23 cm3) of the patients in the observation group had decreased, and which was significantly less than that (112.12±6.20 cm3) of the patients in the control group. Three months after operation, the uterine volume (181.53±8.47 cm3), the levels of E2 (151.24±8.43 pmol/L), LH (10.39±1.85 U/L) and FSH (13.58±2.16 U/L), and the PFDI-20 score of the patients in the observation group were significantly less than those (190.54±9.54 cm3, 168.47±9.34 pmol/L, 12.60±2.85 U/L and 15.39±3.05 U/L) of the patients in the control group (all P<0.05). There was no significant difference in the recurrence rate of uterine myoma of the patients in 6 months after operation between the two groups (P>0.05). The recurrence rate of uterine myoma (0) of the patients in the observation group in 12 months after operation was significantly lower than that (5.0%) of the patients in the control group (P<0.05). Conclusion: Leuprorelin combined with laparoscopic myomectomy for treating patients with uterine myoma has better efficacy, and which can improve their pelvic floor function and ovarian function recoveries and can reduce the recurrence rate of the uterine myoma of the patients in 12 months after operation, and without increase of the complications and with medication safety.
|
|
|
|
|
|
|
|
|
